Germany is considering the purchase of Ukrainian-made "Flamingo" long-range rockets as an alternative to U.S. Tomahawk missiles [1, 2].
This potential acquisition marks a significant shift in European defense procurement. By looking to Ukraine for strategic weaponry, Berlin is attempting to resolve a critical supply shortfall in its long-range arsenal while reducing its reliance on American military hardware.
The move follows a decision by the United States to refuse the deployment of Tomahawk missile units within Germany [1, 2]. This refusal has left the German Ministry of Defence seeking immediate options to replenish its strategic capabilities [1, 2].
Berlin has turned its attention to Fire Point, a Ukrainian defence company co-founded by Denis Shtilerman [1]. The company produces the Flamingo rocket, which is being positioned as a viable substitute for the American system [1, 2].
According to reports from May 14, 2026, the German government is evaluating whether the Ukrainian technology can meet the operational requirements of its armed forces [1]. The pursuit of the Flamingo system suggests a growing trend of Western nations sourcing battle-tested technology from Ukraine, a reversal of the traditional military aid flow.
Officials from the German Ministry of Defence have not yet finalized a procurement contract, but the discussions highlight the urgency of Berlin's need for long-range strike capabilities [1, 2]. The Flamingo rockets would provide a deterrent capability that the U.S. has thus far declined to provide through the Tomahawk program [1, 2].
“Germany is considering the purchase of Ukrainian-made "Flamingo" long-range rockets”
This development signals a pivot in the strategic relationship between the US and Germany, where US restrictions on high-end weaponry are driving European powers toward Ukrainian defense innovation. If finalized, the deal would validate Ukraine's transition from a recipient of military aid to a sophisticated exporter of strategic weaponry, potentially altering the defense industrial landscape in Europe.



